Endothelin antagonist treatment for successful liver transplantation from non-heart-beating donors

BACKGROUND: With the shortage of cadaveric donors, non-heart-beating donors (NHBDs) are a potential source of liver allografts. However, warm ischemic injury in NHBDs seriously affects the viability of graft liver. Endothelin (ET)-1 has been reported to be involved in the hepatic microcirculatory disturbances after ischemia-reperfusion. METHODS: In a porcine orthotopic liver transplantation model, changes in the serum and liver tissue ET-1 concentration were measured and the effects of an ET receptor antagonist, TAK-044, were evaluated. After cardiac arrest of the donors, liver allografts were subjected to 90 min of warm ischemia, flushed, and preserved for 4 hr at 4 degrees C. The pigs were divided into two groups: a control group (no drug treatment) and a drug-treated group, in which donors and recipients were treated with TAK-044 (10 mg/kg body, drip intravenous injection). Both groups had six donor/recipient pairs. RESULTS: -The ET-1 concentration in the hepatic venous blood increased after reperfusion of the graft in the control group recipients. ET-1 in the graft liver significantly increased during the cold preservation period. TAK-044 treatment significantly increased recipient 7-day survival rate. After reperfusion of the graft, the concentrations of serum liver enzymes and arterial lactate in the drug-treated group were significantly lower than in the control group. The postoperative increase in portal venous pressure was significantly reduced in the drug-treated group. Measurements of liver enzymes in the washed-out preservation fluid at the time of graft rinsing indicated that TAK-044 treatment of the donors significantly suppressed liver enzyme release during ischemia. CONCLUSIONS: These findings indicate TAK-044 treatment has protective effects on postoperative function of hepatic allografts procured from NHBDs.     

基于Windows的S12数字程控交换机人机命令查询系统的设计与实现

介绍了基于Windows3.x环境下,用Delphi开发软件,结合面象对象技术、数据库技术、Windows帮助文件系统技术,开发S12数字程控交换机人机命令信息查询系统的过程和方法.并对超文本技术、面向对象技术、数据库技术进行了阐述.通过试运行,验证了本系统的高速、方便、安全、兼容性好等特点.     

儿童白血病患者医院感染的临床分析

目的:探讨儿童白血病患者医院感染的临床特点、严重程度及原因。方法:本文对1989 年～1995 年儿童白血病住院病人发生医院感染情况进行回顾性分析。结果:本组儿童白血病的医院感染( 例次) 率达47-3 % ,以呼吸道感染最多见,病原菌以革兰阴性杆菌占首位,病死率较高。结论:儿童白血病住院病人是医院感染的易感人群,尤其在粒细胞减少期,应加强对这部分病人的管理及合理用药。     

准分子激光PRK术后的临床分析

目的 对１１１眼屈光范围球镜在－３．００￣－１７．００Ｄ及柱镜在－０．５０Ｄ￣－４．５０Ｄ范围的患者进行了ＰＲＫ术后的分析。方法 采用美国ＶＩＳＸ２０／２０Ｂ准分子激光系统的最新软件包进行角膜切削,并行术前后的主客观验光及角膜透明度检查。结果与结论 准分子激光ＰＲＫ术是目前理想的屈光手术之一,特别对于中低度近视尤为适合,对高度近视则其预见性稳定性较差,并发症的发生并未成为影响术后效果的主要因素。     

环孢霉素A滴眼预防高危角膜移植免疫排斥的效果

目标 探讨环孢霉素Ａ（ＣｓＡ）联合地塞米松局部滴眼预防高危穿透角膜移植（ＰＫＰ）免疫排斥反应的效果。方法 将７７眼高危ＰＫＰ分为ＣｓＡ组（３７眼）;２％ＣｓＡ蓖麻油溶液联合地塞米松滴眼;对照组（４０眼）单独使用地塞米松滴眼。采用生存曲线进行比较。结果 术后２年,两组植片存活率分别为８９％和６０％,差异有显著性（Ｐ〈０．０５）。结论 ２％ＣｓＡ蓖麻油溶液联合地塞米松溶液局部滴眼是预防高危ＰＫＰ免疫排     

视力客观检测方法的研究

目的研究用视觉诱发电位（ｖｉｓｕａｌｅｖｏｋｅｄｐｏｔｅｎｔｉａｌ,ＶＥＰ）作为视力客观检测的可行性。方法对４０只视力不等的患眼和５０只正常眼,分别记录用不同大小方格（８°、４°、２°、１°、３０、１５和６）刺激时的ＶＥＰ波形。结果患眼组和正常组Ｐ１００振幅及潜时在统计学上有显著性差异。视力与能诱发出波形的最小方格间有明显关系：最小方格为６、１５、３０和１°,平均视力分别为１．１３,０．６２,０．１８和０．０７。视力与Ｐ１００振幅呈正相关,与潜时呈负相关。结论用诱发出ＶＥＰ波形的最小方格大小可估计患者的视力范围     

Ultrastructural morphometric investigations on rat liver of young and adult rats after treatment with technical pentachlorophenol (PCP)

Age-dependent effects of technical pentachlorophenol (PCP) on male rat livers were investigated after a 15 day treatment with PCP, 30 mg/kg/d body weight. The liver tissues were investigated morphometrically at light and electron microscopical levels. Statistically significant alterations of nuclei and organelles of the hepatocytes were described.This work was supported by the Deutsche Forschungsgemeinschaft — Biologie des Alterns — Th 83/14     

中西医结合治疗宫颈糜烂50例观察

目的：观察恒和坤净栓联合波姆红外光治疗宫项糜烂的疗效。方法：中西医结合组50例用恒和坤净检与波姆红外光治力仪联合治疗；对照组50例，单用波姆红外光治疗仪治疗。结果：中西医结合组痊愈率82％，对照组痊愈率40％。结论：中西医结合疗效较好，优于单用西医治疗。     

IL-2活化瘤苗对胃癌术后复发和转移的抑制作用

目的观察用细胞因子活化的特异性瘤苗辅助常规化疗,治疗外科手术后临床Ⅲ～Ⅳ期胃癌患者,抑制肿瘤术后复发、转移的临床疗效。方法于外科术后常规化疗结束后2周,用患者自体肿瘤细胞抗原致敏、IL-2活化的树突状细胞(DC)作为瘤苗给患者四肢皮下多点免疫注射1×106/(ml·次),每周1次,每疗程注射4次,0.5年后强化1次。定期胃镜、影象学和肿瘤标志物检查,随访至手术后第2年,观察生存期和生存率。结果经瘤苗治疗后,患者的免疫功能显著改善。术后24个月,瘤苗联合化疗组患者的生存率为50%,血清中CEA和CA724分别为(10±1.5)ng/ml和(5.5±1.5)U/ml,而单纯化疗组患者的生存率为10%,CEA和CA724的水平分别为(77.0±9.4)ng/ml和(55.0±7.6)U/ml;P<0.001。结论特异性瘤苗免疫治疗,能增强胃癌患者术后的特异性抗肿瘤免疫功能,提高手术后化疗疗效,抑制肿瘤复发和转移,能延长患者生存期,提高生存率。